Loading
QI
QLT Inc/BC Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by STONEPINE CAPITAL, L.P., was filed 15 Sept 2016.
QLT Inc/BC: what insiders have been doing
This page follows insider dealings at QLT Inc/BC as filed with SEC (Form 4). QLT Inc/BC has had no insider filing for more than a year; the last one goes back to 1 December 2016.
The full history, which starts in 2016, counts 3 purchases against no sales.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
11
Thresholds
n/a
Buy Volume
€183,641
3 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Last declaration on 1 December 2016
Declarations11 total
4,472,940 sharesCommon Shares, without par valueSEC:0001104659-16-160114:0
1,747 sharesCommon Shares, without par valueSEC:0001104659-16-160104:0
175,979 sharesCommon Shares, without par valueSEC:0001104659-16-160115:1
31,280 sharesCommon Shares, without par valueSEC:0001104659-16-160115:2
82,765 sharesCommon Shares, without par valueSEC:0001104659-16-160115:3
4,102 sharesCommon Shares, without par valueSEC:0001104659-16-160112:0
2,963 sharesCommon Shares, without par valueSEC:0001104659-16-160107:0
1,136,363 shares@ US$1.76100.0% of flowCommon Shares, without par valueSEC:0001104659-16-160115:0
61,704 shares@ US$1.5446.1% of flowCommon StockSEC:0001140361-16-079947:0
Canonical exit: 12 Dec 2016 (T+90)
56,864 shares@ US$1.5542.7% of flowCommon StockSEC:0001140361-16-079947:1
Canonical exit: 13 Dec 2016 (T+90)
14,928 shares@ US$1.5511.2% of flowCommon StockSEC:0001140361-16-079947:2
Canonical exit: 14 Dec 2016 (T+90)
11 of 11 declarations
About QLT Inc/BC
QLT Inc/BC is a NASDAQ-listed company focused on developing treatments for ophthalmic diseases. It emphasizes innovation and improving visual healthcare.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
